Shared on15 Aug 25
Despite softer agent and transaction counts, analysts reaffirmed their price target at $2.00, citing better-than-expected Q2 revenue and EBITDA, a favorable product mix shift, and ongoing margin expansion prospects. Analyst Commentary Q2 revenue and EBITDA exceeded expectations, offsetting weaknesses in agent and transaction counts.
Shared on24 Apr 25Fair value Decreased 33%
AnalystConsensusTarget has decreased future PE multiple from 3.0x to 2.0x.
Shared on17 Apr 25Fair value Increased 55%
AnalystConsensusTarget has increased profit margin from 4.4% to 5.2%, increased future PE multiple from 2.3x to 3.0x and decreased shares outstanding growth rate from 0.3% to 0.1%.